Sunitinib-and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages

  Turan, Nedim ^a   Benekli, Mustafa ^a   Ozturk, Selcuk Cemil ^a   Inal, Salih ^a   Memis, Leyla ^a   Guz, Galip ^a   Cetin, Bulent ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Gastrointestinal stromal tumor; Nephrotic syndrome; Sorafenib; Sunitinib

Indexed keywords

IMATINIB; NILOTINIB; RAMIPRIL; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADULT; ANASARCA; ARTICLE; CASE REPORT; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION;

ANGIOGENESIS INHIBITORS; BENZENESULFONATES; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MIDDLE AGED; NEPHROTIC SYNDROME; PYRIDINES; PYRROLES;

EID: 84867770488     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R160     Document Type: Article

References (22)

1. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008;100:282-4.
2. Launay-Vacher V, Derey G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20:81-2.
3. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and re-nal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36.
4. Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T. Sunitinib-in-duced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 2012;16:310-5.
5. Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmen-tal glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 2010;25:1001-3.
6. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy sec-ondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Trans-plant 2009;24:682-5.
7. Rolleman EJ, Weening J, Betjes MG. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant 2009;24:2002-3.
8. Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal fail-ure apparently induced by sunitinib. Case Rep Oncol 2009;2:172-6.
9. Obhrai JS, Patel TV, Humphreys BD. The case/progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 2008;74:685-6.
10. Okuno Y, Kume H, Hosoda C, Homma Y. Development of nephritic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma. Case Rep Med 2011;2011:710216.
11. Jonkers IJ, van Buren M. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol 2009;13:397-401.
12. Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 2010;21:184-5.
13. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcino-ma. Nat Clin Pract Nephrol 2007;3:287-93
14. Winn SK, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009;24:673-5.
15. Izzedine H, Brocheriou I, Rixe O, Deray G. Interstitial nephritis in a pa-tient taking sorafenib. Nephrol Dial Transplant 2007;22:2411.
16. Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007;5:341-4.
17. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities as-sociated with the use of tyrosine kinase inhibitors: A single-center experi-ence and review of the literature. Nephron Clin Pract 2011;117:312-9.
18. Frangié C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Re-nal thrombotic microangiopathy caused by anti-VEGF-antibody treat-ment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-8.
19. Shiiki H, Dohi K, Hanatani M, et al. Focal and segmental glomeruloscle-rosis in preeclamptic patients with nephrotic syndrome. Am J Nephrol 1990;10:205-12.
20. Kappers MH, Smedts FM, Horn T, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011;58:295-302.
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the prob-ability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
22. Rini B, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763-73.